Clinical Trial Update: Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma [Phase 1, Phase 2]

View source ↗

Summary

The completed Phase 1/2 trial evaluated the combination of laboratory-treated T cells with ipilimumab in patients with metastatic melanoma. The study explored s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Laboratory-Treated T Cells (adoptive T cell therapy)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Recurrent Melanoma, Stage IV Melanoma | Phase 1, Phase 2 | Status: COMPLETED